Similar findings were seen in the EGFR-positive NSCLC cohort, where 66 of 389 patients (17.0%) were upstaged from AJCC7 to AJCC8 (eTable 3 in the Supplement). This evidence concerns the gene EGFR and non-small cell lung carcinoma.